Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.

Sun XY, Jiang HL, Ma YT, Xiong TQ, Leng XY, Zhao YF, Shen XF, Zhang C, Tang YJ

Journal of translational medicine26 May 2026

PMID42192439PMCIDPMC13386775DOI10.1186/s12967-026-08219-6PepBankPUB-42192439

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with MASLD and fibrosis stages F1-F3, survodutide 6 mg/week was significantly more effective than placebo for NASH resolution without worsening of fibrosis in the network analysis (RR = 7.25, 95% CI 2.07 to 25.36).
In plain wordsIn adults with fatty liver disease and mild to moderate scarring, survodutide 6 mg/week helped more people reach NASH resolution than placebo.
Peptide
Survodutide
Outcome
IncreaseNASH resolution without worsening of fibrosis (network estimate)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
6 mg/weekAs given in this study (human).
Measurements
RR
7.25
survodutide 6 mg/week vs placebo, network estimate
95% CI
2.07 to 25.36
survodutide 6 mg/week vs placebo, network estimate
Source sentences
Summary
survodutide 6 mg/week (RR = 7.25, 95%CI: 2.07, 25.36)
2 context sentences(design, population, supporting numbers)
Summary · context
were significantly more effective for achieving NASH resolution without worsening of fibrosis.
Summary · context
Randomized controlled trials involving adults with MASLD and fibrosis stages of F1-F3 who received pharmacological interventions for improving liver fibrosis from three databases were identified from inception to July 21, 2025.
Report a problemFND-4219243901
02HumanSystematic reviewEfficacy outcome
In adults with MASLD and fibrosis stages F1-F3, survodutide 6 mg/week was significantly more effective than placebo for NASH resolution in direct comparisons (RR = 7.25, 95% CI 2.68 to 19.60).
In plain wordsIn adults with fatty liver disease and mild to moderate scarring, direct comparisons showed survodutide 6 mg/week was more effective than placebo for NASH resolution.
Peptide
Survodutide
Outcome
IncreaseNASH resolution without worsening of fibrosis (direct comparison)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
6 mg/weekAs given in this study (human).
Measurements
RR
7.25
survodutide 6 mg/week vs placebo, direct comparison
95% CI
2.68 to 19.6
survodutide 6 mg/week vs placebo, direct comparison
Source sentences
Summary
survodutide 6 mg/week (RR = 7.25, 95%CI: 2.68, 19.60)
2 context sentences(design, population, supporting numbers)
Summary · context
were significantly more effective than placebo.
Summary · context
Randomized controlled trials involving adults with MASLD and fibrosis stages of F1-F3 who received pharmacological interventions for improving liver fibrosis from three databases were identified from inception to July 21, 2025.
Report a problemFND-4219243902
03HumanSystematic reviewEfficacy outcome
In the network meta-analysis, survodutide 6 mg/week ranked first among the interventions for NASH resolution without worsening of fibrosis (SUCRA 92.0%), ahead of tirzepatide 15 mg/week (89.9%).
In plain wordsIn the pooled analysis, survodutide 6 mg/week ranked best of the tested drugs for NASH resolution, ahead of tirzepatide 15 mg/week.
Peptide
Survodutide
Outcome
Not applicableSUCRA ranking for NASH resolution
Study
n: not reported in source
Comparator
Other pharmacotherapies
Outcome group
Liver fat and liver function · Liver
Studied dose
6 mg/weekAs given in this study (human).
Measurements
SUCRA
92%
survodutide 6 mg/week
Source sentences
Summary
The ranking based SUCRA showed that survodutide 6 mg/week (92.0%) demonstrated the best efficacy, followed by tirzepatide 15 mg/week (89.9%), whereas emricasan 10 mg/day had the poorest efficacy (8.1%).
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving adults with MASLD and fibrosis stages of F1-F3 who received pharmacological interventions for improving liver fibrosis from three databases were identified from inception to July 21, 2025.
Report a problemFND-4219243903
04HumanSystematic reviewEfficacy outcome
In adults with MASLD and fibrosis stages F1-F3, tirzepatide 5 mg/week was more effective than placebo for NASH resolution without worsening of fibrosis in the network meta-analysis (RR 4.29).
In plain wordsIn adults with fatty liver disease, tirzepatide 5 mg weekly was more effective than placebo for resolving NASH without worse fibrosis.
Peptide
Tirzepatide
Outcome
IncreaseNASH resolution without worsening of fibrosis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
5 mg/weekAs given in this study (human).
Measurements
RR
4.29 ratio
tirzepatide 5 mg/week, network
Source sentences
Summary
tirzepatide 5 mg/week (RR = 4.29, 95%CI: 1.33, 13.82)
3 context sentences(design, population, supporting numbers)
Summary · context
were significantly more effective for achieving NASH resolution without worsening of fibrosis.
Summary · context
Randomized controlled trials involving adults with MASLD and fibrosis stages of F1-F3 who received pharmacological interventions for improving liver fibrosis from three databases were identified from inception to July 21, 2025.
Summary · context
Thirteen RCTs involving 3,871 patients with 12 pharmacological interventions were involved.
Report a problemFND-4219243904
05HumanSystematic reviewEfficacy outcome
In adults with MASLD and fibrosis stages F1-F3, tirzepatide 10 mg/week was more effective than placebo for NASH resolution without worsening of fibrosis in the network meta-analysis (RR 5.31).
In plain wordsIn adults with fatty liver disease, tirzepatide 10 mg weekly was more effective than placebo for resolving NASH without worse fibrosis.
Peptide
Tirzepatide
Outcome
IncreaseNASH resolution without worsening of fibrosis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
10 mg/weekAs given in this study (human).
Measurements
RR
5.31 ratio
tirzepatide 10 mg/week, network
Source sentences
Summary
tirzepatide 10 mg/week (RR = 5.31, 95%CI: 1.67, 16.85)
3 context sentences(design, population, supporting numbers)
Summary · context
were significantly more effective for achieving NASH resolution without worsening of fibrosis.
Summary · context
Randomized controlled trials involving adults with MASLD and fibrosis stages of F1-F3 who received pharmacological interventions for improving liver fibrosis from three databases were identified from inception to July 21, 2025.
Summary · context
Thirteen RCTs involving 3,871 patients with 12 pharmacological interventions were involved.
Report a problemFND-4219243905
06HumanSystematic reviewEfficacy outcome
In adults with MASLD and fibrosis stages F1-F3, tirzepatide 15 mg/week was more effective than placebo for NASH resolution without worsening of fibrosis in the network meta-analysis (RR 6.00).
In plain wordsIn adults with fatty liver disease, tirzepatide 15 mg weekly was more effective than placebo for resolving NASH without worse fibrosis.
Peptide
Tirzepatide
Outcome
IncreaseNASH resolution without worsening of fibrosis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
15 mg/weekAs given in this study (human).
Measurements
RR
6 ratio
tirzepatide 15 mg/week, network
Source sentences
Summary
tirzepatide 15 mg/week (RR = 6.00, 95%CI: 1.91, 18.89)
3 context sentences(design, population, supporting numbers)
Summary · context
were significantly more effective for achieving NASH resolution without worsening of fibrosis.
Summary · context
Randomized controlled trials involving adults with MASLD and fibrosis stages of F1-F3 who received pharmacological interventions for improving liver fibrosis from three databases were identified from inception to July 21, 2025.
Summary · context
Thirteen RCTs involving 3,871 patients with 12 pharmacological interventions were involved.
Report a problemFND-4219243906
07HumanSystematic reviewEfficacy outcome
In direct comparisons in adults with MASLD and fibrosis stages F1-F3, tirzepatide 5 mg/week was more effective than placebo (RR 4.29).
In plain wordsIn direct comparisons, tirzepatide 5 mg weekly worked better than placebo in adults with fatty liver disease.
Peptide
Tirzepatide
Outcome
IncreaseNASH resolution without worsening of fibrosis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
5 mg/weekAs given in this study (human).
Measurements
RR
4.29 ratio
tirzepatide 5 mg/week, direct
Source sentences
Summary
tirzepatide 5 mg/week (RR = 4.29, 95%CI: 1.76, 10.43)
3 context sentences(design, population, supporting numbers)
Summary · context
were significantly more effective than placebo.
Summary · context
Randomized controlled trials involving adults with MASLD and fibrosis stages of F1-F3 who received pharmacological interventions for improving liver fibrosis from three databases were identified from inception to July 21, 2025.
Summary · context
Thirteen RCTs involving 3,871 patients with 12 pharmacological interventions were involved.
Report a problemFND-4219243907
08HumanSystematic reviewEfficacy outcome
In direct comparisons in adults with MASLD and fibrosis stages F1-F3, tirzepatide 10 mg/week was more effective than placebo (RR 5.31).
In plain wordsIn direct comparisons, tirzepatide 10 mg weekly worked better than placebo in adults with fatty liver disease.
Peptide
Tirzepatide
Outcome
IncreaseNASH resolution without worsening of fibrosis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
10 mg/weekAs given in this study (human).
Measurements
RR
5.31 ratio
tirzepatide 10 mg/week, direct
Source sentences
Summary
tirzepatide 10 mg/week (RR = 5.31, 95%CI: 2.23, 12.66)
3 context sentences(design, population, supporting numbers)
Summary · context
were significantly more effective than placebo.
Summary · context
Randomized controlled trials involving adults with MASLD and fibrosis stages of F1-F3 who received pharmacological interventions for improving liver fibrosis from three databases were identified from inception to July 21, 2025.
Summary · context
Thirteen RCTs involving 3,871 patients with 12 pharmacological interventions were involved.
Report a problemFND-4219243908
09HumanSystematic reviewEfficacy outcome
In direct comparisons in adults with MASLD and fibrosis stages F1-F3, tirzepatide 15 mg/week was more effective than placebo (RR 6.00).
In plain wordsIn direct comparisons, tirzepatide 15 mg weekly worked better than placebo in adults with fatty liver disease.
Peptide
Tirzepatide
Outcome
IncreaseNASH resolution without worsening of fibrosis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
15 mg/weekAs given in this study (human).
Measurements
RR
6 ratio
tirzepatide 15 mg/week, direct
Source sentences
Summary
tirzepatide 15 mg/week (RR = 6.00, 95%CI: 2.54, 14.15)
3 context sentences(design, population, supporting numbers)
Summary · context
were significantly more effective than placebo.
Summary · context
Randomized controlled trials involving adults with MASLD and fibrosis stages of F1-F3 who received pharmacological interventions for improving liver fibrosis from three databases were identified from inception to July 21, 2025.
Summary · context
Thirteen RCTs involving 3,871 patients with 12 pharmacological interventions were involved.
Report a problemFND-4219243909
10HumanSystematic reviewEfficacy outcome
In the network meta-analysis, tirzepatide 15 mg/week ranked second for efficacy by SUCRA (89.9%), after survodutide 6 mg/week.
In plain wordsIn a ranking of liver treatments, tirzepatide 15 mg weekly came second, after survodutide.
Peptide
Tirzepatide
Outcome
Not applicableSUCRA ranking for efficacy
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
15 mg/weekAs given in this study (human).
Measurements
SUCRA
89.9%
tirzepatide 15 mg/week
Source sentences
Summary
The ranking based SUCRA showed that survodutide 6 mg/week (92.0%) demonstrated the best efficacy, followed by tirzepatide 15 mg/week (89.9%), whereas emricasan 10 mg/day had the poorest efficacy (8.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving adults with MASLD and fibrosis stages of F1-F3 who received pharmacological interventions for improving liver fibrosis from three databases were identified from inception to July 21, 2025.
Summary · context
Thirteen RCTs involving 3,871 patients with 12 pharmacological interventions were involved.
Report a problemFND-4219243910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms

Keywords